Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ibuprofen/Pseudoephedrine FDC vs RhinAdvil
NCT02963701Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibuprofen + pseudoephedrine in common cold and nasal congestion (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point of Ibuprofen at 30 hours, Maximum Concentration of Ibuprofen in Plasma at 30 hours and 2 more. Started Dec 2016; status: completed.
02
Drugs
ibuprofen + pseudoephedrine
03
Conditions
common coldnasal congestion
Beyond the preview
Go deeper on NCT02963701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963701.